

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA

Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

Final appraisal determination

(when no ACD was issued)

1. Have any potential equality issues been identified during the scoping process been addressed by the committee, and, if so, how?
None identified.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?
None identified.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?
None identified.

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable.

7. Have the committee's considerations of equality issues been described in the appraisal consultation determination, and, if so, where?
Not applicable.

Approved by Associate Director (name): Janet Robertson

Date: 23 March 2021

Technology Appraisals: Guidance development
Equality impact assessment for the Single Technology Appraisal of trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
Issue date: June 2021